BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, January 17, 2025
See today's BioWorld Science
Home
» Silo Pharma to study binding affinity of SPU-21 in human synovial tissue for rheumatoid arthritis
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Musculoskeletal
Silo Pharma to study binding affinity of SPU-21 in human synovial tissue for rheumatoid arthritis
Nov. 24, 2022
No Comments
Silo Pharma Inc. plans to initiate a pilot study of SPU-21, its novel joint-homing peptide targeting rheumatoid arthritis (RA), in human synovial tissue surrounding joints and tendons.
BioWorld Science
Inflammatory
Musculoskeletal
Peptide
